ITGAX and neoplasm: Conversely, stromal regions were associated with a substantial abundance of lineage-defining immune markers (CD3, CD8, CD4, CD20, CD14, CD11C), confirming a complex, but tumor-excluded immune environment prior to treatment in most patients regardless of response status (Fig. 3b).